Spring Bank Pharmaceuticals logo

SBPH Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

Healthcare Biotechnology SIC: Unknown CIK: 1566373

Transaction DateRecipientSharesTypePriceValue
Jodie Insights Rating